3.8 Review

Spotlight on the SAPIEN 3 transcatheter heart valve

Journal

MEDICAL DEVICES-EVIDENCE AND RESEARCH
Volume 11, Issue -, Pages 353-360

Publisher

DOVE MEDICAL PRESS LTD
DOI: 10.2147/MDER.S143897

Keywords

aortic valve stenosis; transcatheter aortic valve implantation; TAVI; transcatheter heart valves; Edwards SAPIEN 3

Funding

  1. Boston Scientific
  2. Abbott
  3. Biotronik
  4. Edwards Lifesciences
  5. Symetis SA
  6. SJM

Ask authors/readers for more resources

Transcatheter aortic valve implantation (TAVI) is increasingly performed in patients with severe aortic stenosis. The efficacy and safety have been demonstrated in large randomized trials in patients with high- or intermediate operative risk. With latest-generation transcatheter heart valve (THV) systems, growing operator experience and improved patient selection, clinical outcome has significantly improved with a decline of TAVI-related complications. In this review, the Edwards SAPIEN 3 THV is discussed in terms of technology, procedural advances and complication trends and future developments.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available